Division of Medical Oncology, Department of Internal Medicine, the Ohio State University Wexner Medical Center - Comprehensive Cancer Center, Columbus, USA.
College of Pharmacy, the Ohio State University Wexner Medical Center - Comprehensive Cancer Center, Columbus, USA.
Expert Rev Anticancer Ther. 2022 Aug;22(8):861-874. doi: 10.1080/14737140.2022.2094772. Epub 2022 Jul 4.
Immune checkpoint inhibitors (ICI) are now utilized as a standard of care treatment for multiple cancers, including in both the metastatic setting as well as in earlier stages of disease. The identification of unique immune-related adverse events (irAE) that occur during ICI treatment has led to intense research to identify potential risk factors and biomarkers that may assist in clinical decision making. Although initial studies in ICI were primarily in advanced stage disease, the use of ICI in earlier stages of disease as adjuvant therapies requires a better understanding of patient risk stratification to mitigate or prevent serious irAE.
In this review, we set out to describe the current state of research regarding potential risk factors for irAE in patients with non-small cell lung cancer, as well as explore the barriers to understanding irAE. We review data from irAE that occur in large phase 3 trials and prospective studies focusing on irAE, as well as the many retrospective studies that currently form the bulk of our understanding of irAE.
免疫检查点抑制剂（ICI）现在被用作多种癌症的标准治疗方法，包括在转移性疾病和疾病早期阶段。在 ICI 治疗过程中发现了独特的免疫相关不良事件（irAE），这促使人们进行了大量研究，以确定可能有助于临床决策的潜在风险因素和生物标志物。尽管最初的 ICI 研究主要针对晚期疾病，但作为辅助疗法在疾病早期阶段使用 ICI 需要更好地了解患者的风险分层，以减轻或预防严重的 irAE。
在这篇综述中，我们旨在描述目前关于非小细胞肺癌患者 irAE 潜在风险因素的研究现状，并探讨理解 irAE 的障碍。我们回顾了来自大型 III 期试验和专注于 irAE 的前瞻性研究的数据，以及目前构成我们对 irAE 理解大部分的许多回顾性研究。
